Protara Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on developing cancer and rare disease therapies, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 12:30 pm ET in New York. Additionally, management will join the TD Cowen 6th Annual Oncology Innovation Summit for a virtual fireside chat on May 27, 2025, at 1:30 pm ET. Both events will be webcast live and temporarily archived on the company's investor relations website.

News Market Reaction

-1.53%

1 alert

-1.53% News Effect

On the day this news was published, TARA declined 1.53%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:

• H.C. Wainwright & Co. 3^rd Annual BioConnect Investor Conference. A fireside chat will take place on Tuesday, May 20, 2025 at 12:30 pm ET in New York.
• TD Cowen 6^th Annual Oncology Innovation Summit. A fireside chat will take place virtually on Tuesday, May 27, 2025 at 1:30 pm ET.

A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

FAQ

When is Protara Therapeutics (TARA) presenting at the H.C. Wainwright BioConnect Conference?

Protara Therapeutics will present at the H.C. Wainwright BioConnect Conference on Tuesday, May 20, 2025 at 12:30 pm ET in New York.

Where can I watch Protara Therapeutics' (TARA) investor conference presentations?

The presentations can be accessed through the Events and Presentations section of Protara's website at https://ir.protaratx.com.

What type of company is Protara Therapeutics (TARA)?

Protara Therapeutics is a clinical-stage company that develops transformative therapies for the treatment of cancer and rare diseases.

When is Protara Therapeutics' (TARA) presentation at the TD Cowen Oncology Innovation Summit?

Protara Therapeutics will present virtually at the TD Cowen Oncology Innovation Summit on Tuesday, May 27, 2025 at 1:30 pm ET.